These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 19463066)

  • 21. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta.
    Hurwitz BJ
    J Neurol Sci; 2008 Sep; 272(1-2):8-19. PubMed ID: 18620708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
    Ebers GC; Reder AT; Traboulsee A; Li D; Langdon D; Goodin DS; Wolf C; Beckmann K; Konieczny A;
    Clin Ther; 2009 Aug; 31(8):1724-36. PubMed ID: 19808131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies.
    Antel JP; Miron VE
    Clin Neurol Neurosurg; 2008 Nov; 110(9):951-7. PubMed ID: 18502570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
    Wiendl H; Hohlfeld R
    Neurology; 2009 Mar; 72(11):1008-15. PubMed ID: 19289741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Oral therapy for multiple sclerosis!].
    de Seze J
    Rev Neurol (Paris); 2010 Apr; 166(4):363-4. PubMed ID: 20385331
    [No Abstract]   [Full Text] [Related]  

  • 27. Injection of interferon-beta in the morning decreases flu-like syndrome in many patients with multiple sclerosis.
    Nadjar Y; Coutelas E; Prouteau P; Panzer F; Paquet D; Saint-Val C; Créange A
    Clin Neurol Neurosurg; 2011 May; 113(4):316-22. PubMed ID: 21269761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behind the paper: saved from the drain.
    Dolgin E
    Nat Med; 2010 Apr; 16(4):378. PubMed ID: 20376044
    [No Abstract]   [Full Text] [Related]  

  • 29. Quality of Life Assessment in Patients with Multiple Sclerosis Receiving Interferon Beta-1a: A Comparative Longitudinal Study of Avonex and Its Biosimilar CinnoVex.
    Abolfazli R; Hosseini A; Gholami Kh; Javadi MR; Torkamandi H; Emami S
    ISRN Neurol; 2012; 2012():786526. PubMed ID: 22928117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.
    Cepok S; Schreiber H; Hoffmann S; Zhou D; Neuhaus O; von Geldern G; Hochgesand S; Nessler S; Rothhammer V; Lang M; Hartung HP; Hemmer B
    Arch Neurol; 2009 Oct; 66(10):1216-23. PubMed ID: 19667211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.
    Carroll WM
    Mult Scler; 2009 Aug; 15(8):951-8. PubMed ID: 19465446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.
    Girouard N; Théorêt G
    Can J Neurosci Nurs; 2008; 30(4):18-25. PubMed ID: 19146204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G
    Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcified subcutaneous nodules: a long-term complication of interferon beta-1a therapy.
    Macbeth AE; Kendall BR; Smith A; Saldanha G; Harman KE
    Br J Dermatol; 2007 Sep; 157(3):624-5. PubMed ID: 17596164
    [No Abstract]   [Full Text] [Related]  

  • 35. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Zipoli V; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Lepore V; Livrea P; Comi G; Amato MP;
    Ann Neurol; 2009 Oct; 66(4):513-20. PubMed ID: 19847899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measures in the first year of therapy predict the response to interferon beta in MS.
    Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
    Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mitoxantrone for the treatment of patients with multiple sclerosis].
    Komori M; Kondo T; Tanaka M
    Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis.
    Vandenbark AA; Huan J; Agotsch M; La Tocha D; Goelz S; Offner H; Lanker S; Bourdette D
    J Neuroimmunol; 2009 Oct; 215(1-2):125-8. PubMed ID: 19758707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR; Cadavid D; Wolansky L; Skurnick J
    Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.